TY - JOUR
T1 - Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer
AU - Li, Tingting
AU - Shi, Sixiang
AU - Goel, Shreya
AU - Shen, Xue
AU - Xie, Xiaoxue
AU - Chen, Zhongyuan
AU - Zhang, Hanxi
AU - Li, Shun
AU - Qin, Xiang
AU - Yang, Hong
AU - Wu, Chunhui
AU - Liu, Yiyao
N1 - Funding Information:
This work was supported, in part or in whole, by the National Natural Science Foundation of China ( 31470959 , 81671821 , 81471785 , 11772088 , 31700811 , 11802056 , 31800780 ), the China Scholarship Council ( 201606070070 ), the Research Program of Sichuan Science and Technology ( 2017JY0019 , 2017JY0217 , 19YYJC0073 , 19YYJC0071 ), the China Postdoctoral Science Foundation ( 2017JY0217 , 2018M640904 ), and the Fundamental Research Funds for the Central Universities ( ZYGX2016Z001 ).
Publisher Copyright:
© 2019 Acta Materialia Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/4/15
Y1 - 2019/4/15
N2 - Recently, drug delivery systems based on nanotechnology have received great attention in cancer therapeutics and diagnostics since they can not only improve the treatment efficacy but also reduce the side effects. Among them, mesoporous silica nanoparticles (MSNs) with large surface area, high pore volume, tunable pore size, abundant surface chemistry, and acceptable biocompatibility exhibit unique advantages and are considered as promising candidates for cancer diagnosis and therapy. In this review, we update the recent progress on MSN-based systems for cancer treatment purposes. We also discuss the drug loading mechanism of MSNs, stimuli-responsive drug release, and surface modification strategies for improving biocompatibility, and targeting functionalities. Statement of Significance: The development of MSN-based delivery systems that can be used in both diagnosis and treatment of cancer has attracted tremendous interest in the past decade. MSN-based delivery systems can improve therapeutic efficacy and reduce cytotoxicity to normal tissue. To further improve the in vivo properties of MSNs and potential translation to the clinics, it is critical to design MSNs with appropriate surface engineering and desirable cancer targeting. This review is intended to provide the readers a comprehensive background of the vast literature till date on silica-based drug delivery systems, and to inspire further innovations in silica nanomedicine in the future.
AB - Recently, drug delivery systems based on nanotechnology have received great attention in cancer therapeutics and diagnostics since they can not only improve the treatment efficacy but also reduce the side effects. Among them, mesoporous silica nanoparticles (MSNs) with large surface area, high pore volume, tunable pore size, abundant surface chemistry, and acceptable biocompatibility exhibit unique advantages and are considered as promising candidates for cancer diagnosis and therapy. In this review, we update the recent progress on MSN-based systems for cancer treatment purposes. We also discuss the drug loading mechanism of MSNs, stimuli-responsive drug release, and surface modification strategies for improving biocompatibility, and targeting functionalities. Statement of Significance: The development of MSN-based delivery systems that can be used in both diagnosis and treatment of cancer has attracted tremendous interest in the past decade. MSN-based delivery systems can improve therapeutic efficacy and reduce cytotoxicity to normal tissue. To further improve the in vivo properties of MSNs and potential translation to the clinics, it is critical to design MSNs with appropriate surface engineering and desirable cancer targeting. This review is intended to provide the readers a comprehensive background of the vast literature till date on silica-based drug delivery systems, and to inspire further innovations in silica nanomedicine in the future.
KW - Biocompatibility
KW - Combination therapy
KW - Mesoporous silica nanoparticles (MSNs)
KW - Stimuli-responsive release
UR - https://www.scopus.com/pages/publications/85062105054
U2 - 10.1016/j.actbio.2019.02.031
DO - 10.1016/j.actbio.2019.02.031
M3 - Review article
C2 - 30797106
AN - SCOPUS:85062105054
SN - 1742-7061
VL - 89
SP - 1
EP - 13
JO - Acta Biomaterialia
JF - Acta Biomaterialia
ER -
